Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
Register now or login to post to this thread.

Any views on Astrazeneca (AZN)     

Ranjith - 07 Dec 2003 22:31

Got a good line of products, but the share price seem to go down , could it be due to the weak us dollar.

HARRYCAT - 23 Sep 2014 11:15 - 37 of 92

Down 5% due to the following:
Deutsche Bank "The US Treasury has announced a package of measures designed to stop US companies taking advantage of inversion deals, including "spin-versions". These appear more far-reaching than anticipated (although they are not retroactive for deals already completed). It is unclear whether the moves threaten completion of to-be-consummated deals, given that other benefits (cost savings, pipeline expansion, strategic elements) may still be sufficient to justify such deals proceeding and that the extent to which the Treasury changes impact the financial benefits cannot be quantified externally (we await the first formal response from one of the pending US acquirors). Regarding AstraZeneca, we note that Pfizer never quantified the extent to which tax benefits were important to its evaluation of the company and thus - with other strategic attractions (oncology pipeline, EM expansion etc) - it is unclear to us whether, or to what extent, the overnight news materially diminishes the chance of Pfizer renewing its interest post 26 November."

midknight - 24 Oct 2014 13:01 - 38 of 92

Green light in Europe for AZN ovarian cancer drug

midknight - 24 Oct 2014 13:08 - 39 of 92

Also: News

midknight - 05 Feb 2015 15:45 - 40 of 92

,Results and news

Feb 5:

Berenberg: Hold - TP: 4800p
Jefferies: Buy - TP: 5600p,
Liberum Capital: Buy - TP: 5800p
Shore Capital: Buy

midknight - 06 Feb 2015 10:10 - 41 of 92

Feb 6:
Panmure Gordon: Buy - TP: 5000p
Beaufort Securities: Hold - TP: N/A
Deutsche Bank: Hold - TP: 4800p

midknight - 06 Feb 2015 10:49 - 42 of 92

Questor/Telegraph says Hold/Solid long term investment

midknight - 09 Feb 2015 10:29 - 43 of 92

Feb 9: Citigroup: Buy - TP: 5400p

skinny - 09 Feb 2015 10:35 - 44 of 92

Questor share tip: AstraZeneca remains solid long term investment

midknight - 10 Feb 2015 10:02 - 45 of 92

Feb 10: Barclays: Underweight - TP: 4400p

midknight - 13 Feb 2015 12:56 - 46 of 92

Feb 13: Credit Suisse -Neutral - TP: 4670p

midknight - 16 Feb 2015 10:32 - 47 of 92

AZN Airways

midknight - 16 Feb 2015 11:20 - 48 of 92

Astra Zeneca's patent on asthma drug invalidated by US court

midknight - 17 Feb 2015 10:47 - 49 of 92

Astra considering appeal

midknight - 20 Feb 2015 09:52 - 50 of 92

Feb 20: Jefferies: Buy - TP: 5600p

midknight - 24 Feb 2015 09:56 - 51 of 92

Feb 24:

Kepler Cheuvreux: Reduce - TP: 3700p
Credit Suisse: Neutral - TP: 4670p

midknight - 25 Feb 2015 10:39 - 52 of 92

Feb 25:
Citigroup: Buy - TP: 5400p
JP Morgan: Neutral - TP: 4300p

midknight - 10 Mar 2015 10:33 - 53 of 92

Mar 10:
Jefferies:: Buy - TP: 5600p
JP Morgan: Neutral - TP: 4300p



midknight - 11 Mar 2015 09:59 - 54 of 92

Mar 11; Citigroup: Buy - TP: 5400p

midknight - 16 Mar 2015 10:04 - 55 of 92

Mar 16:

Credit Suisse: Neutral - TP: 4320p
Kepler Cheuvreux: Reduce - TP: 3700p
Jefferies: Buy - TP: 5600p
Deutsche Bank: Hold - TP: 4800p

midknight - 17 Mar 2015 10:18 - 56 of 92

Mar 17:
Exane BNP : Outperform - TP: 5400p
Beaufort: Hold
JP Morgan: Neutral
Register now or login to post to this thread.